LFCR vs MRK · rev $75.5M vs P/E 33, rev $16.61B
Lifecore Biomedical Inc. (LFCR) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Lifecore Biomedical Inc. (LFCR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Robert M. Davis J.D..
Latest reported LFCR revenue for 2025-12-31 was $75.5M. Net income was -$18.0M. Revenue was up 771.6% from 2025-06-30 to 2025-12-31. LFCR currently screens at market cap $207.1M.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
LFCR currently screens at market cap $207.1M. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the LFCR and MRK stock pages for the full models.
Not investment advice.